Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kindstar Globalgene Technology, Inc. ( (HK:9960) ) just unveiled an announcement.
Kindstar Globalgene Technology has announced amendments to a partnership agreement governing an investment fund in which it participates, extending the fund’s overall duration to May 8, 2029. The partnership will now have a three-year investment period starting May 8, 2024, followed by a two-year payback period, with the option to extend both phases by unanimous partner consent, provided the total term does not exceed six years.
To align with the longer investment horizon, the partners agreed that the management fee for the newly added third year of the investment period will be charged at the lower rate used in the payback phase, set at 1.5% annually of the fund’s total cost of remaining investments as of the prior year-end. Other terms of the partnership remain unchanged, implying a modest structural adjustment aimed at balancing longer deployment of capital with a more conservative fee structure, which may benefit limited partners while giving Kindstar and its partners more flexibility in executing investment strategies.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical and genetic technology sector. The company focuses on specialized diagnostic and laboratory services, positioning itself in high-value healthcare testing and related technology-driven services for the Greater China market and beyond.
Average Trading Volume: 400,173
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.21B
See more insights into 9960 stock on TipRanks’ Stock Analysis page.